A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.
Vignot
Stéphane
S
Khayat
David
D
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002986:Clinical Trials as Topic; D000069448:Denosumab; D006801:Humans; D010024:Osteoporosis / Q000517:prevention & control; D053245:RANK Ligand / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab